Recently, Jiangxi, Yunnan, Gansu, and Shanxi provinces issued notices on the implementation of national negotiating drugs. Previously, 15 provinces including Anhui, Beijing, Henan, Fujian, and Hubei have clearly defined the methods for negotiating varieties into provincial medical insurance catalogues. In this regard, some experts said that as domestically produced innovative drugs and generic drugs enter the medical insurance catalogue through negotiation mechanisms and comprehensively implement negotiated prices nationwide, the competition will become more intense. In the future, competition between local enterprises and multinational pharmaceutical companies should focus more on Innovation.
According to the relevant regulations of the Ministry of Human Resources and Social Security, the social security departments of the provinces (autonomous regions and municipalities) may not transfer the successfully negotiated drugs out of the medical insurance catalogue, nor adjust the limited payment range. According to industry insiders, 36 kinds of special drugs that entered the medical insurance catalogue covered multiple disease areas, and the price cuts were obvious. The price advantage of domestic competitive drugs was not obvious.
It is understood that in the past, domestically produced drugs and similar imported drugs usually compete at low prices in competition. At present, imported drugs have actively lowered prices into medical insurance through negotiation mechanisms, which has weakened the price advantage of domestically produced drugs and increased the pressure of competition. At the same time, the room for patients to choose Medicare drugs increases.
Taking Novartis's 10%/ml*0.2ml injection of Rauma monoclonal antibody as an example, the price dropped from 7125 yuan/branch to 5700 yuan/piece before the negotiation, a decrease of 20%. The price of domestic similar products Compaqip 10mg/ml*0.2ml injection was reduced from 6725 yuan/piece before negotiation to 5555 yuan/piece, a decrease of 17.40%, and the difference between the two was only 145 yuan. After the inclusion of Raychemizumab and Compaqip, the eligible patients can obtain medicines by paying 30% at their own expense, greatly reducing the economic burden.
"Currently, foreign-invested original drugs and domestic generic drugs are used, mainly in the price of drugs. With the introduction of the medical insurance catalogue, the price gap between the two is narrowing." Director of Ophthalmology, Beijing Tongren Hospital, Capital Medical University Wei Wenbin believes: "I believe that patients will choose drugs that are more clinically tested. Domestic companies must work hard to innovate."
In addition, the negotiation mechanism has become an important way for high-priced innovative drugs to enter the medical insurance catalog. A major advantage of drug price negotiations is to achieve mutual benefit through consultation and cooperation. Under the traditional directory review mechanism, although the drug is negotiated, the clinical effect is good, but it is difficult to enter the medical insurance catalog because of the high price. The negotiation mechanism provides a communication channel to allow high-priced innovative drugs to be included in the scope of medical insurance reimbursement through the "market space for price discounts" approach. Drug price negotiation will help improve the accessibility of patients' medications, improve the risk control ability of medical insurance funds, ensure the profits of pharmaceutical companies, and promote the development of medical technology.
Dong Zhaohui, deputy director of the Medical Insurance Research Office of the Social Security Research Institute of the Ministry of Human Resources and Social Security, said that the human and social departments have promised that the drugs negotiated will be included in the management and medical insurance reimbursement according to the B drugs, which must be implemented in all places and at the same time Monitor work to prevent abuse of these high-priced drugs. Secondly, in the negotiation agreement for 36 kinds of drugs, there is already a medical insurance payment price, and it is unlikely that there will be obvious price fluctuations. Therefore, the local health and family planning departments responsible for drug bidding and procurement should allow public hospitals to independently purchase negotiating drugs to avoid clinical shortage. . Finally, pharmaceutical companies should adequately supply drugs at negotiated prices to avoid drug shortages, while also complying with drug marketing practices to prevent drug abuse.
Dong Zhaohui believes that the negotiation mechanism should become the main way for high-priced innovative drug insurance access, and it should be normalized in the future. First, it is necessary to further standardize the evidence of negotiations and further refine the procedures, which will help to raise the consensus of the parties to the negotiations. Second, further improve the policy synergy of relevant government departments, such as drug circulation, procurement, and safeguard policies. Third, pharmaceutical companies should pay more attention to the cost performance of products, and use scientific and authentic evidence to prove the pharmacoeconomic value of drugs. Fourth, relevant departments and enterprises should also establish a negotiated drug supply channel, because many of the drugs negotiated are rare drugs, which are difficult and costly to circulate and store. They need government, enterprises, medical institutions and related organizations. Work together.
Source: China News Network
Vault Secures,Vault Door,Movable Vault Room,Vault For Bank
Hebei Yingbo Safe Boxes Co.,Ltd , https://www.yingbosafebox.com